Myasthenia gravis - In-depth characterization of antibody-specific pathomechanisms and identification of novel autoantibodies.

Myasthenia gravis - In-depth characterization of antibody-specific pathomechanisms and identification of novel autoantibodies. - MYA-IN-DEPTH

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025711

Enrollment

150

Registered

2021-09-07

Start date

2021-09-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70.0

Interventions

Group 1: Seronegative MG patients: Intercostal muscle biopsy will be performed only if it results in diagnostic and/or therapeutic consequences (e.g. diagnostic uncertainty or in refractory cases to e

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patient capable of written informed consent - Adult patients MG patients: - Seronegative MG patients for whom an intercostal muscle biopsy is planned within standard care (i.e. in case of diagnostic uncertainty or in case of therapy refractory disease course to assess the possibility of a targeted complement inhibition) - AchR-Ak-positive MG patients for whom thymectomy is planned as part of standard care (“positive controls”). Participants of the control group (“negative controls”): - Patients for whom a thoracoscopy/thoracotomy is planned for a non-myasthenic indication (e.g. traumatic injuries)

Exclusion criteria

Exclusion criteria: Participants in the control group (negative controls): - Known rheumatic or tumor diseases

Design outcomes

Primary

Measure	Time frame
The study will demonstrate that specific immunological pathomechanisms can be identified depending on the autoantibody status in MG patients.	—

Secondary

Measure	Time frame
Furthermore, it will be investigated whether 1) Autoantibody-specific changes of the neuromuscular endplate can be shown by ultrastructural analysis (electron microscopy) 2) Previously unknown changes in the neuromuscular endplate in MG patients can be detected using novel array tomography (3D electron microscopy) and nanotomy (large-scale digitization for 2D electron microscopy) 3) New autoantibodies against postsynaptic structures of the neuromuscular endplate can be identified in the blood and/or plasma products of seronegative MG patients using indirect immunofluorescence tests (IIFT) and mass spectroscopy.	—

Measure

Time frame

Furthermore, it will be investigated whether 1) Autoantibody-specific changes of the neuromuscular endplate can be shown by ultrastructural analysis (electron microscopy) 2) Previously unknown changes in the neuromuscular endplate in MG patients can be detected using novel array tomography (3D electron microscopy) and nanotomy (large-scale digitization for 2D electron microscopy) 3) New autoantibodies against postsynaptic structures of the neuromuscular endplate can be identified in the blood and/or plasma products of seronegative MG patients using indirect immunofluorescence tests (IIFT) and mass spectroscopy.

—

Countries

Germany

Contacts

Public ContactSarah Hoffmann

Klinik für Neurologie, Charité - Universitätsmedizin Berlin

sarah.hoffmann@charite.de+49-30-450539724

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026